Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Patrick Assyag"'
Autor:
Philippe Charron, Patricia Reant, Karine Nguyen, Patrick Assyag, Mariana Mirabel, Anju Duva Pentiah
Publikováno v:
Archives des Maladies du Coeur et des Vaisseaux - Pratique. 2016:16-23
Autor:
Marie-Christine Iliou, C. Chong-Nguyen, Michel Galinier, Barnabas Gellen, Charles Taieb, Florence Beauvais, Théo Pezel, Patrick Assyag, T. Hemery, N. De Nadai, Yves Juillière, Damien Logeart, P. De Groote, Etienne Audureau, Thibaud Damy, Emmanuelle Berthelot
Publikováno v:
Archives of Cardiovascular Diseases Supplements. 10:33
Background Heart Failure (HF) is a major public health problem resulting in high rates of hospitalization and mortality. Current HF guidelines recommend sodium-restricted dietary approaches to prevent acute HF, but adherence to salt restriction may b
Autor:
Alain Cohen-Solal, Robert Boukobza, Henry Krys, Magali Viaud, Yann Bourgueil, Thomas Renaud, Ariel Cohen, Aleksandra Bundalo, Patrick Assyag, Pierre-Louis Michel
Publikováno v:
Archives of Cardiovascular Diseases. 102(1):29-41
Summary Background Heart failure presents a major public health problem due to its high prevalence and the increasing number of hospital admissions for this condition. A coordinated healthcare network involving general practitioners and cardiologists
Autor:
Pascal de Groote, Richard Isnard, Guillaume Jondeau, Patrick Assyag, Michel Komajda, Michel Galinier, Pierre Clerson, A. Ducardonnet, Jean-François Thébaut, Nacima Demil
Publikováno v:
European Journal of Heart Failure. 11:85-91
Aims Recent studies have shown that prescription rates and doses of recommended drugs for chronic heart failure (CHF) are not optimal in daily practice. The aim of the Impact-Reco programme was to analyse prescription rates of CHF drugs in stable out
Publikováno v:
JAMA internal medicine. 174(10)
Autor:
Maxime Genoun, Patrick Assyag, Alain Cohen Solal, Jean-François Thébaut, Christine Contre, Pierre Clerson, Florence Beauvais, I. Leurs
Publikováno v:
Archives of cardiovascular diseases. 105(6-7)
Summary Background No clinical practice guidelines are available for the treatment of heart failure (HF) in patients with preserved left ventricular ejection fraction (LVEF). Aims To determine how cardiologists manage medical treatment in HF patients
Autor:
Guillaume Jondeau, Jean-François Thébaut, Michel Galinier, Nacima Demil, Pascal de Groote, Richard Isnard, A. Ducardonnet, Patrick Assyag, Michel Komajda
Publikováno v:
Archives of Cardiovascular Diseases Supplements. 2(1)
Background The prevalence of anaemia in chronic heart failure (CHF) ranges widely from 4 to 70% due to a lack of an established consistent definition of anaemia in CHF. Furthermore haemodilution impacts haemoglobin concentrations and could be an impo
Autor:
Patrick Assyag, Michel Komajda, Michel Galinier, P. de Groote, Jean-François Thébaut, Guillaume Jondeau, Pierre Clerson, I. Leurs, Richard Isnard, A. Ducardonnet
Publikováno v:
European journal of heart failure. 9(12)
Recent registries have shown that recommended drugs for the treatment of chronic heart failure (CHF) are under-prescribed in daily practice.To determine prescription rates of CHF drugs, and to assess predictive factors for drug prescription using dat
Autor:
Isabelle Boutron, Louise Boyer-Chatenet, Patrick Assyag, Philippe Ravaud, Alain Cohen-Solal, Gilles Montalescot, Marie Dalichampt, Michel Pl, Christel Perdrix, Ariel Cohen, P. Gabriel Steg
Publikováno v:
JAMA Internal Medicine. 174:40
Importance Lifestyle improvements after an acute coronary syndrome reduce cardiovascular risk but are difficult to achieve. Objective To determine whether a nurse-led or dietician-led cardiovascular risk factor education program would improve risk fa
Autor:
Guillaume Jondeau, Patrick Assyag, Michel Komajda, Nacima Demil, Jean-François Thébaut, Richard Isnard, A. Ducardonnet, Michel Galinier, Pascal de Groote
Publikováno v:
Archives of Cardiovascular Diseases Supplements. 2(1):27-28
BackgroundThe recent European Guidelines for the treatment of CHF 2008 underlined that the majority of patient with CHF and COPD can safely tolerate β-blocker therapy.AimsThe IMPACT-RECO program III analysed the impact of NYHA class and of comorbidi